Catalyst Crew Technologies Corp. (OTC: CCTC) today announced the development of NeuroAI, an artificial intelligence-enabled module designed to support neurological analysis and predictive risk modeling. The platform is intended to assist healthcare providers in analyzing neurological data and identifying potential clinical risks through AI-driven analytics.
NeuroAI's proposed capabilities include early detection of neurological abnormalities, predictive modeling of cerebrovascular events, and AI-assisted analysis of brain imaging and cognitive data. The platform integrates multiple data inputs, such as magnetic resonance imaging (MRI), electroencephalograms (EEG), cognitive assessments, and patient-specific data, to generate structured outputs that support clinical review and care coordination.
As part of Catalyst Crew's broader AI healthcare platform, NeuroAI is expected to function as a specialized module within the company's digital health ecosystem. Management believes that modular AI systems like NeuroAI may support scalable deployment across telehealth services, remote monitoring, and technology-enabled healthcare delivery environments.
The company intends to integrate NeuroAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform. As development progresses, NeuroAI is expected to support data-driven insights and clinical decision-support capabilities across neurological care pathways.
Catalyst Crew Technologies is prioritizing market development in Latin America, where AI-enabled healthcare technologies may help expand access to neurological evaluation tools, support early identification of conditions, and improve healthcare system efficiency.
Dr. Kevin Rodan Levy, Chief Executive Officer, stated: "Advancements in artificial intelligence present new opportunities to assist in the early identification and monitoring of neurological conditions. NeuroAI is part of our broader strategy to develop integrated, scalable healthcare technologies that can support medical professionals and improve patient care."
For more information, visit https://catalystcrewai.com or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
